Dynemicin A is an anti-cancer drug of the enediyne class, a natural product of the soil bacterium Micromonospora chersina that was first isolated from soil in the Gujarat State of India. It has a bright purple color from its anthraquinone chromophore, and it was originally isolated for its use as a dye before research turned to its anti-cancer properties. Bristol-Myers elucidated its structure in Japan by X-ray diffraction of a closely related compound, triacetyldynemicin A, and Myers and coworkers reported the first chemical synthesis. It acts on B-DNA by intercalating into the minor groove; once bound, its epoxide is activated and the enediyne undergoes a re-cyclization that cleaves both DNA strands and leads to cell death. The source describes it as promising for cancer treatment but still requiring further research, and its pharmacology is not yet fully explored.
Facts
Drug ClassEnediyne antitumor antibiotic 2 Mechanism of ActionA benzenoid biradical formed from the enediyne core cleaves DNA 3 First Approved / Isolated Year Classification
ATC ClassL: Antineoplastic and Immunomodulating Agents 1 Connections
Sources
1. Dynemicin A (Wikipedia)
2. The biosynthetic genes encoding for the production of the dynemicin enediyne core in Micromonospora chersina ATCC53710
AbstractQuote, Abstract
Dynemicin is a novel anthraquinone-fused member of the 10-membered enediyne antitumor antibiotic family.
View the Source 3. Module 2: Synthesis/Biosynthesis of Enediynes Class of Natural Products, Lecture 2
2.2.2. Dynemicins
It is the benzenoid biradical that is actually responsible for the cleavage of the DNA molecule
2.2.2. Dynemicins, structure
The dynemicins has a striking hybrid structure that contains (a) the cyclic enediyne, (b) an anthraquinone chromophore.
View the Source4. Dynemicin A biosynthesis article (PubMed Central PMC5944350)
Introductory text before Figure 1Quote, Introductory text before Figure 1
Produced by Micromonospora chersina, dynemicin A was first discovered in 1989,
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.